Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 59.8%

Neg 59.8% Neu 0% Pos 0%

Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3 to $2.